Q3 25 EPS
$-0.94
MISS 19.50%
Est. $-0.79
Q3 25 Revenue
$2.8M
MISS 88.06%
Est. $23.1M
vs S&P Since Q3 25
+82.9%
BEATING MARKET
KYMR +93.9% vs S&P +10.9%
Market Reaction
Did KYMR Beat Earnings? Q3 2025 Results
Kymera Therapeutics delivered a sharply disappointing third quarter, missing on both the top and bottom lines as the clinical-stage biotech continued to funnel capital into its targeted protein degradation pipeline. The company posted a loss of $0.94… Read more Kymera Therapeutics delivered a sharply disappointing third quarter, missing on both the top and bottom lines as the clinical-stage biotech continued to funnel capital into its targeted protein degradation pipeline. The company posted a loss of $0.94 per share, coming in 19.50% below the consensus estimate of $0.79, while collaboration revenue of $2.76 million fell 88.06% short of the $23.14 million Wall Street had anticipated and declined 26.1% from the year-ago period. The primary culprit was a surge in R&D spending to $74.09 million, reflecting intensified investment in KT-621, the company's first-in-class STAT6 degrader, which has completed enrollment in its BroADen Phase 1b atopic dermatitis trial with full data expected in December 2025. Despite the shortfalls, Kymera's $978.74 million cash position provides runway into the second half of 2028, supporting parallel Phase 2b programs in atopic dermatitis and asthma alongside the anticipated Phase 1 entry for its IRF5 degrader KT-579 in early 2026, keeping the longer-term pipeline story largely intact even as quarterly results disappointed.
Key Takeaways
- • Increased R&D investment in STAT6 program, platform, and discovery programs
- • Collaboration revenue from Gilead Sciences partnership
- • Interest income of $10.4 million partially offsetting operating losses
KYMR YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
KYMR Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our team has made impressive research, clinical, and regulatory progress this quarter to advance our first-in-class oral degrader medicines, and we look forward to several important milestones through the fourth quarter and early next year. We've completed patient enrollment and dosing in the KT-621 BroADen Phase 1b trial in AD, marking a significant moment in the industry as the first STAT6-directed agent in patients, and we plan to share the full data set next month. Additionally, we've initiated the KT-621 BROADEN2 Phase 2b trial in AD and are on track to start BREADTH, the Phase 2b asthma study, in the first quarter of 2026, positioning us on an accelerated development path to multiple registrational studies across areas of significant unmet need.”
— Nello Mainolfi, Q3 2025 Earnings Press Release
KYMR Earnings Trends
KYMR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
KYMR EPS Trend
Earnings per share: estimate vs actual
KYMR Revenue Trend
Quarterly revenue: estimate vs actual
KYMR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.85 | $-0.71 | +16.07% | $34.4M | +317.57% |
| Q4 25 MISS FY | $-0.79 | $-0.97 | -23.10% | $2.9M | -80.61% |
| FY Full Year | $-3.47 | $-3.69 | -6.46% | $39.2M | -26.90% |
| Q3 25 MISS | $-0.79 | $-0.94 | -19.50% | $2.8M | -88.06% |
| Q2 25 MISS | $-0.80 | $-0.95 | -19.12% | $11.5M | -52.51% |
| Q1 25 BEAT | $-0.91 | $-0.82 | +9.90% | $22.1M | +105.88% |